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To ascertain characteristics of pandemic (H1N1) 
2009 virus infection, we reviewed medical records for all 
suspected or conﬁ  rmed cases reported in Abu Dhabi dur-
ing May 2009–March 2010. Overall case-fatality rate was 
1.4/100,000 population. Most patients who died had ≥1 risk 
factor, and female decedents were considerably younger 
than male decedents.
T
he outbreak of pandemic (H1N1) 2009 inﬂ  uenza virus 
was ﬁ  rst noted in Mexico in March 2009 (1) but quick-
ly spread worldwide. On June 11, 2009, the World Health 
Organization declared the ﬁ  rst inﬂ  uenza pandemic in >40 
years, triggering governments around the world to make 
pandemic (H1N1) 2009 a top public health priority (2). Al-
though numerous published studies from around the world 
have described experiences with the pandemic, few have 
been from the Middle East. In this study, we present data 
from Abu Dhabi, the largest of the 7 states in the United 
Arab Emirates. Abu Dhabi is also the country’s capital and 
has a population of ≈2 million (3).
The Study
By May 1, 2009, Abu Dhabi had procedures in place 
for reporting suspected or conﬁ  rmed cases of pandemic 
(H1N1) 2009 (4). The state government made reporting 
mandatory, and data were recorded by Health Authority 
Abu Dhabi (HAAD). All health care facilities in Abu Dhabi 
were provided with the case deﬁ  nition of pandemic (H1N1) 
2009 virus infection along with reporting guidelines (re-
vised September 8, 2009) (4). Brieﬂ  y, inﬂ  uenza-like illness 
(ILI) was deﬁ  ned as fever (>37.8°C) with cough and/or sore 
throat in the absence of known causes other than inﬂ  uenza. 
Pandemic (H1N1) 2009 was conﬁ  rmed by using real-time 
reverse transcription–PCR according to protocol (5). Labo-
ratory testing was recommended only for patients with se-
vere illness (ILI with signs such as hypotension, dyspnea, 
tachypnea, abnormal radiographic appearance of the lungs) 
or patients with mild illness who had risk factors (e.g., preg-
nancy, age <5 years, chronic disease). All patients who had 
symptoms of inﬂ  uenza but negative test results by PCR 
for pandemic (H1N1) 2009 or who were not tested were 
grouped into the ILI category for statistical analysis. 
Data was analyzed using PASW Statistics version 
18 (SPSS Inc, Chicago, IL, USA). One-way analysis of 
variance was used to compare differences in mean age 
between the 3 groups (ILI, conﬁ  rmed pandemic [H1N1] 
2009 infections, pandemic [H1N1] 2009–associated 
deaths) and the χ2 test (2-sided) to compare gender and 
national origin of patients.
From May 1, 2009, through March 23, 2010, a total 
of 2,806 patients with conﬁ  rmed or suspected pandemic 
(H1N1) 2009 infection were reported to HAAD. The ﬁ  rst 
ILI case was recorded on May 3; the number of cases 
peaked in August (Figure 1). The ﬁ  rst laboratory-conﬁ  rmed 
case occurred on May 20, with the ﬁ  rst pandemic (H1N1) 
2009–associated death on September 1. Laboratory-con-
ﬁ  rmed pandemic (H1N1) 2009 cases showed a bimodal 
distribution, with the ﬁ  rst peak in August and the second 
peak in October (Figure 1). The lack of a second peak in the 
ILI group is probably due to the change in testing recom-
mendations issued by HAAD on September 8 (testing only 
patients with severe illness or with risk factors).
Of the 2,806 patients reported, 1,872 (67%) had ILI, 
908 (32%) had laboratory-conﬁ   rmed pandemic (H1N1) 
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Figure 1. Distribution of cases of inﬂ  uenza-like illness (ILI), laboratory 
conﬁ  rmed-pandemic (H1N1) 2009 in patients who survived, and 
pandemic (H1N1) 2009 in patients who died, Abu Dhabi, United 
Arab Emirates, May 1, 2009–March 23, 2010. Of the 2,806 cases 
reported to Health Authority Abu Dhabi, 1,872 were ILI (pandemic 
[H1N1] 2009 negative or status unknown), 908 were conﬁ  rmed 
pandemic (H1N1) 2009 infections in patients who survived, and 
26 were pandemic (H1N1) 2009 infections in patients who died. 
Patients with ILI and survivors of conﬁ  rmed pandemic (H1N1) 2009 
are plotted by date patient ﬁ  rst sought care. Pandemic (H1N1) 2009 
fatalities are plotted by date of death.Pandemic (H1N1) 2009, Abu Dhabi
2009 infection and survived, and 26 (0.9%) had pandemic 
(H1N1) 2009 infection and died (Table 1). Of the 2,806 pa-
tients, 60% (1,679) were male; the preponderance of male 
patients most likely reﬂ  ects the substantially higher popu-
lation of male than female residents in Abu Dhabi (3). Of 
the 1,872 patients with ILI, 646 had laboratory-conﬁ  rmed 
negative results for pandemic (H1N1) 2009; the remain-
ing patients were not tested. Almost half (439/896, or 49%) 
of all laboratory-conﬁ  rmed cases occurred in children and 
young adults <20 years of age (Figure 2). For 12 laborato-
ry-conﬁ  rmed cases, the precise age of the patient was not 
known. Most (21/26, 81%) decedents were 21–60 years of 
age; 1 reason may be that the overall population of Abu 
Dhabi is skewed toward younger age groups. Men who died 
of pandemic (H1N1) 2009 were signiﬁ  cantly older (mean 
age 52.9 years, 95% conﬁ  dence interval [CI] 44.0–61.7) 
than their female counterparts (mean age 31.5 years, 95% 
CI 18.9–44.1; Mann-Whitney U test, p = 0.007) (Table 2). 
However, these ﬁ  ndings have to be interpreted with caution 
because our sample of patient deaths is small.
Abu Dhabi has a high expatriate population. Accord-
ing to HAAD 2009 statistics (3), 78.8% of the population 
consists of persons who are not citizens of the United Arab 
Emirates. Patients in our study represented >50 different 
nationalities, the top 5 being Emirati, Indian, Filipino, 
Egyptian, and Pakistani. To have sufﬁ  cient numbers for 
a meaningful statistical analysis, we grouped all reported 
cases into United Arab Emirate nationals (n = 1,708) or 
expatriates (n = 1,098). Analysis of these 2 groups showed 
no signiﬁ  cant age difference (1-way analysis of variance, p 
= 0.357) between the Emiratis and the expatriates in terms 
of ILI, pandemic (H1N1) 2009 survivors, and pandemic 
(H1N1) 2009 decedents.
Of the 26 decedents, 15 were male; 12 were United 
Arab Emirate nationals, and 14 were expatriates. Calcu-
lating case-fatality rates (CFR) with laboratory-conﬁ  rmed 
cases as the denominator is, in this type of study, inaccurate 
and misleading. Because not all persons with symptoms 
seek medical attention or are tested, pandemic (H1N1) 
2009–conﬁ  rmed cases are likely to be underestimated and 
CFR, in turn, to be grossly overestimated (6,7). We chose 
to represent mortality estimates per 100,000 persons be-
cause the number of fatal cases and the population are ac-
curately known. This information gave an estimated CFR 
of 1.4 deaths per 100,000 persons. The mean age of dece-
dents was 43.8 years compared with 21.6 years for persons 
with laboratory-conﬁ  rmed pandemic (H1N1) 2009 infec-
tion who survived (1-way analysis of variance, p<0.01). 
The most common initial symptoms were fever, cough, 
and breathing difﬁ  culty (Table 2). All patients with pan-
demic (H1N1) 2009 who died received oseltamivir; how-
ever, complete details of antiviral treatment were available 
for only 21/26 cases. For 20 patients, treatment was started 
before or on the day of laboratory conﬁ  rmation (mean −3.2 
days). Mean duration of antiviral treatment was 8.3 days 
(range 2–28 days). Most (20/26; 77%) patients with pan-
demic (H1N1) 2009 who died had >1 underlying risk factor 
(8), most commonly pregnancy, diabetes, malignancy, and 
hypertension. Twelve decedents each had 1 risk factor, 3 
had 2, 3 had 3, and 2 had 4. Mean duration from hospital 
admission to death was 27.5 days (Table 2).
Ages of decedents with pandemic (H1N1) 2009 infec-
tion differed signiﬁ  cantly by gender; female patients were 
considerably younger (mean 31.5 years) than male patients 
(mean 52.9 years). Even after excluding pregnant women 
from the equation (9), female decedents remained signiﬁ  -
cantly younger than male decedents. In contrast, ages of 
survivors of pandemic (H1N1) 2009 infection did not differ 
signiﬁ  cantly by sex. 
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Figure 2. Age group distribution of patients with inﬂ  uenza-like 
illness and laboratory-conﬁ  rmed pandemic (H1N1) 2009 infection, 
Abu Dhabi, United Arab Emirates, May 1, 2009–March 23, 2010.
Table 1. Number of cases of influenza-like illness, laboratory-confirmed pandemic (H1N1) 2009, and pandemic (H1N1) 2009– 
associated deaths, Abu Dhabi, United Arab Emirates, May 1, 2009–March 23, 2010* 
Illness Total no. cases  Incidence†
Mean age, y 
All patients  Male patients Female patients
Influenza-like illness  1,872  97.7 23.0 22.5 23.7
Pandemic (H1N1) 2009 
   Survived  908 47.4 21.6 20.7 22.7
 Died  26 1.4 43.8 52.9 31.5
*Based on Heath Authority Abu Dhabi statistics for 2009 (3). The emirate of Abu Dhabi has a total population of 1,915,903. 
†Per 100,000 population. Conclusions
In this study from the United Arab Emirates, we re-
port the epidemiologic and clinical features of pandemic 
(H1N1) 2009 infection in Abu Dhabi. The characteristics 
are similar to those reported in other parts of the world (10–
12). Children were most at risk for pandemic (H1N1) 2009 
infection; older adults (>60 years) appeared to be least af-
fected, probably because of cross-protective immunity from 
exposure to antigenically related inﬂ  uenza viruses earlier 
in life (13,14). Twenty-six persons died, most of whom 
were 21–60 years of age (7,10). This number translates to 
an overall incidence of pandemic (H1N1) 2009–associated 
death in Abu Dhabi of 1.4/100,000 population, which is 
relatively low compared with some studies (11,15). 
Our ﬁ  ndings are subject to limitations. For example, 
like most epidemiologic studies based on surveillance sys-
tems, data are often incomplete, and therefore resulting 
analysis can be subject to bias. Nonetheless, we believe 
the aggressive approach implemented by the Abu Dhabi 
government (e.g., body temperature scans at airports, isola-
tion of persons suspected to have pandemic [H1N1] 2009, 
tracing of contacts of persons with conﬁ  rmed cases, and 
providing oseltamivir prophylaxis) played an important 
role, not only in delaying the onset and spread of pandemic 
(H1N1) 2009, but also in reducing deaths. 
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